<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Varenicline (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Varenicline (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Varenicline (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="134148" href="/d/html/134148.html" rel="external">see "Varenicline (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="134172" href="/d/html/134172.html" rel="external">see "Varenicline (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56297853"><span class="drugH1">Brand Names: US</span>
<ul>
<li>APO-Varenicline;</li>
<li>Chantix Continuing Month Pak [DSC];</li>
<li>Chantix Starting Month Pak [DSC];</li>
<li>Chantix [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56297990"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Varenicline;</li>
<li>Champix;</li>
<li>Champix Starter Pack;</li>
<li>TEVA-Varenicline</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F56299671"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Partial Nicotine Agonist</span>;</li>
<li>
<span class="list-set-name">Smoking Cessation Aid</span></li></ul></div>
<div class="block dop drugH1Div" id="F56297896"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e049a955-ebdd-4184-a38a-1676817bbf2f">Smoking cessation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Smoking cessation:</b> Adolescents ≥17 years: <b>Note:</b> Efficacy has not been established in patients &lt;17 years of age; a randomized, double-blind, placebo-controlled trial including 216 pediatric patients 12 to 16 years of age showed that varenicline did not improve continuous abstinence rates; use is not recommended in pediatric patients ≤16 years of age. In another double-blind, placebo-controlled trial of 157 adolescents and young adults 14 to 19 years of age (mean age: 19.1 ± 1.5 years), the primary efficacy endpoint of end of treatment (week 12) abstinence was the same in both treatment and placebo groups at 8.9%; significant findings in secondary endpoints were observed, including higher weekly self-reported abstinence rates, and patients who achieved 7-day abstinence reported shorter time to achieve 7 days abstinence (39 days compared to 59 days with placebo) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31609433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31609433'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: See "Approaches to selecting a tobacco quit date" for additional information.</p>
<p style="text-indent:-2em;margin-left:6em;">Days 1 to 3: Oral: 0.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Days 4 to 7: Oral: 0.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance (≥ Day 8): Oral: 1 mg twice daily for 11 weeks; may consider a temporary or permanent dose reduction if usual dose is not tolerated. If patient successfully quits smoking at the end of the 12 weeks, may continue for another 12 weeks to help maintain success. Patients who are motivated to quit and do not succeed in stopping smoking during prior therapy, or who relapse after treatment, should be encouraged to make another attempt with varenicline once factors contributing to the failed attempt have been identified and addressed.</p>
<p style="text-indent:-2em;margin-left:4em;">Approaches to selecting a tobacco quit date: May either choose a fixed quit date (ie, start varenicline, then quit on day 8) or a flexible quit date (ie, start varenicline, then quit between days 8 to 35). Alternatively, a gradual quit date (ie, start varenicline and reduce smoking 50% by week 4, reduce an additional 50% by week 8, and continue reducing with a goal of complete abstinence by week 12) is acceptable.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Adolescents ≥17 years: Patients who cannot tolerate adverse events may require temporary (or permanent) reduction in dose.</p></div>
<div class="block dorp drugH1Div" id="F56297837"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Adolescents ≥17 years:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Initial: 0.5 mg once daily; maximum maintenance dose: 0.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) (receiving hemodialysis): Maximum maintenance dose: 0.5 mg once daily.</p></div>
<div class="block dohp drugH1Div" id="F56297835"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Adolescents ≥17 years: No dosage adjustment necessary.</p></div>
<div class="block doa drugH1Div" id="F56297895"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="134148" href="/d/html/134148.html" rel="external">see "Varenicline (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e049a955-ebdd-4184-a38a-1676817bbf2f">Smoking cessation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Smoking cessation:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used as monotherapy or in combination with nicotine replacement therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32663106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32663106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Initial:</p>
<p style="text-indent:-2em;margin-left:6em;">Days 1 to 3: 0.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Days 4 to 7: 0.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance (day 8 and later): 1 mg twice daily; may consider a temporary or permanent dose reduction if usual dose is not tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16820548','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16820548','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Duration: Continue maintenance dose for at least 11 weeks (for a total of at least 12 weeks of treatment). May consider extended maintenance therapy based on individual patient risk:benefit; evidence suggests relapse prevention benefits with continuing therapy for up to 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32663106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32663106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Approaches to selecting a tobacco quit date: May either choose a fixed quit date (ie, start varenicline, then quit on day 8) or a flexible quit date (ie, start varenicline, then quit between days 8 to 35). Alternatively, a gradual quit date (ie, start varenicline and reduce smoking 50% by week 4, reduce an additional 50% by week 8, and continue reducing with a goal of complete abstinence by week 12) is acceptable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21518946','lexi-content-ref-Rigotti.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21518946','lexi-content-ref-Rigotti.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56297836"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: Initial: 0.5 mg once daily; maximum maintenance dose: 0.5 mg twice daily</p>
<p style="text-indent:-2em;margin-left:2em;">ESRD (receiving hemodialysis): Maximum dose: 0.5 mg once daily</p></div>
<div class="block doha drugH1Div" id="F56297834"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block arsc drugH1Div" id="F56297871"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A 2011 meta-analysis suggested a potential increased risk of cardiovascular events with varenicline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21727225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21727225'])">Ref</a></span>). However, this has not been observed in several subsequent studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25083271','lexi-content-ref-26903004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25083271','lexi-content-ref-26903004'])">Ref</a></span>). To further investigate the potential cardiovascular risk, the FDA requested a 52-week non-treatment extension of the EAGLES Trial, finding no increase in the composite of cardiovascular death, nonfatal <b>acute myocardial infarction</b>, or nonfatal stroke in patients treated with varenicline versus placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29630702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29630702'])">Ref</a></span>). While data are inconclusive regarding whether treatment increases the risk of cardiovascular events, the risk appears lower than nicotine replacement therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29630702','lexi-content-ref-32077187','lexi-content-ref-26903004','lexi-content-ref-23615317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29630702','lexi-content-ref-32077187','lexi-content-ref-26903004','lexi-content-ref-23615317'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action; hypothesized to be due to effects on nicotinic acetylcholine receptors which may impact cardiovascular function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29630702','lexi-content-ref-26903004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29630702','lexi-content-ref-26903004'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Disordered sleep</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal dreams</b> and <b>nightmares</b> have occurred with use. Cases of <b>somnambulism</b> (sleepwalking), involving harmful behavior to self, others, or property have also been reported, which generally resolve with treatment discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25409105','lexi-content-ref-25767129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25409105','lexi-content-ref-25767129'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. May also be related to nicotine withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25409105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25409105'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; reported between 1 day and 1 to 2 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25409105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25409105'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nausea</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dose-dependent <b>nausea</b> may occur; both transient and persistent nausea have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27158893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27158893'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action; effects on nicotinic acetylcholine receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21606948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21606948'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; usually begins within first 2 weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31502736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31502736'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27158893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27158893'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuropsychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Postmarketing cases of serious neuropsychiatric events (including <b>depression</b>, <b>suicidal ideation</b>, and <b>suicidal behavior</b>) have been reported in patients with or without preexisting psychiatric disease; some cases may have been complicated by symptoms of nicotine withdrawal following smoking cessation. Subsequent controlled trials in patients with stable psychiatric disorders or those without psychiatric disorders, however, have not identified significant differences in neuropsychiatric effects for patients taking varenicline, bupropion, nicotine patches, or placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27116918','lexi-content-ref-24042367','lexi-content-ref-24030388','lexi-content-ref-25767129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27116918','lexi-content-ref-24042367','lexi-content-ref-24030388','lexi-content-ref-25767129'])">Ref</a></span>). Many postmarketing cases resolved following therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbid psychiatric illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27116918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27116918'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Seizures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Postmarketing cases of <b>seizures</b> have been reported in patients with or without a history of seizures; however, subsequent observational studies have not shown a definitive association (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27158893','lexi-content-ref-31252274','lexi-content-ref-21287775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27158893','lexi-content-ref-31252274','lexi-content-ref-21287775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action; possibly due to activation of α<sub>4</sub>β<sub>2 </sub>or α<sub>7</sub> nicotinic acetylcholine receptors which can increase intracellular calcium levels and thus epileptic activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24906297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24906297'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; risk greatest within first month of treatment course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26514264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26514264'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• First month of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26514264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26514264'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56297870"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (16% to 40%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 1</a>)</span><span class="table-link" style="display:none;">Nausea</span>, vomiting (5% to 11%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Varenicline: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Varenicline)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Varenicline)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">821</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">805</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">256</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">269</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients with major depressive disorder</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,982</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,979</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients with or without a history of psychiatric disorder</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">43</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients with stable schizophrenia or schizoaffective disorder</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">129</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">805</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (8% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Abnormal dreams table link" class="lexi-table-link" data-table-id="lexi-content-abnormal-dreams" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abnormal-dreams')">table 2</a>)</span><span class="table-link" style="display:none;">Abnormal dreams</span>, depressed mood (≤11%), headache (12% to 19%), insomnia (9% to 19%), irritability (11%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abnormal dreams" frame="border" id="lexi-content-abnormal-dreams" rules="all">
<caption style="text-align:center;">
<b>Varenicline: Adverse Reaction: Abnormal dreams</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Varenicline)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Varenicline)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">821</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">805</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,007</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">997</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients with a history of psychiatric disorder</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">256</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">269</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients with major depressive disorder</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">129</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">805</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">975</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">982</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients without a history of psychiatric disorder</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (≤1%), angina pectoris (4%), chest pain (3%), peripheral edema (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Menstrual disease, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (7%), anorexia (≤2%), constipation (5% to 8%), decreased appetite (≤2%), diarrhea (6%), dysgeusia (5% to 8%), dyspepsia (5%), flatulence (6% to 9%), gastroesophageal reflux disease (1%), increased appetite (3% to 4%), toothache, xerostomia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (5% to 7%), anxiety (8%), disturbance in attention, dizziness, drowsiness (3%), emotional disturbance (5%), fatigue (≤7%), hostility (2% to 3%), lethargy (1% to 2%), malaise (≤7%), nightmares (1% to 2%)<span class="lexi-table-link-container"> (<a aria-label="Nightmares table link" class="lexi-table-link" data-table-id="lexi-content-nightmares" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nightmares')">table 3</a>)</span><span class="table-link" style="display:none;">Nightmares</span>, sleep disorder (2% to 5%<span class="lexi-table-link-container"> (<a aria-label="Sleep Disorder table link" class="lexi-table-link" data-table-id="lexi-content-sleep-disorder" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sleep-disorder')">table 4</a>)</span><span class="table-link" style="display:none;">Sleep Disorder</span>), tension (4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nightmares" frame="border" id="lexi-content-nightmares" rules="all">
<caption style="text-align:center;">
<b>Varenicline: Adverse Reaction: Nightmares</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Varenicline)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Varenicline)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">129</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">805</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">821</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">805</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sleep Disorder" frame="border" id="lexi-content-sleep-disorder" rules="all">
<caption style="text-align:center;">
<b>Varenicline: Adverse Reaction: Sleep Disorder</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Varenicline)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Varenicline)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">821</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">805</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">975</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">982</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients without a history of psychiatric disorder</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,007</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">997</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients with a history of psychiatric disorder</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">129</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">805</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, asthenia (≤7%), back pain, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (2%), respiratory system disorder, rhinorrhea (≤1%), upper respiratory tract infection (5% to 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute coronary syndrome, atrial fibrillation, bradycardia, cardiac arrhythmia, cardiac flutter, cerebrovascular accident, chest discomfort, coronary artery disease, ECG abnormality, edema, flushing, ophthalmic vascular disease, palpitations, pulmonary embolism, syncope, tachycardia, thrombosis, transient ischemic attacks, ventricular premature contractions</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, eczema, erythema of skin, hyperhidrosis, psoriasis, skin photosensitivity, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, diabetes mellitus, hyperlipidemia, hypoglycemia, hypokalemia, thyroid disease</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis, dysphagia, enterocolitis, eructation, esophagitis, gallbladder disease, gastric ulcer, gastritis, gastrointestinal hemorrhage, intestinal obstruction, oral mucosa ulcer</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal urine test finding, erectile dysfunction, nocturia, pollakiuria, sexual difficulty, urethral disease, urinary retention, urine abnormality</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, leukocytosis, lymphadenopathy, splenomegaly, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal sensory symptoms, abnormality in thinking, altered sense of smell, amnesia, balance impairment, Bell's palsy, bradyphrenia, chills, decreased mental acuity, difficulty thinking, disorientation, dissociative disorder, dysarthria, emotional lability, euphoria, migraine, psychomotor agitation, psychomotor impairment, restless leg syndrome, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, elevation in serum levels of skeletal-muscle enzymes, multiple sclerosis, muscle cramps, musculoskeletal pain, myositis, osteoporosis, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, cataract (subcapsular), conjunctivitis, eye irritation, eye pain, night blindness, nystagmus disorder, photophobia, transient blindness, visual field defect, vitreous opacity, xerophthalmia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness, Meniere's disease, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, nephrolithiasis, polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Allergic rhinitis, asthma, cor pulmonale, epistaxis, flu-like symptoms, pleurisy, upper respiratory tract inflammation</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Seak 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, behavioral changes, delusion, depression (Anthenelli 2016), hallucination, homicidal ideation, lack of concentration, loss of consciousness, mania, panic, paranoid ideation, psychosis, somnambulism (Savage 2015, Thomas 2015), suicidal behavior (Anthenelli 2016), suicidal ideation (Anthenelli 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (Molero 2015)</p></div>
<div class="block coi drugH1Div" id="F56297867"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Serious hypersensitivity reactions or skin reactions to varenicline or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F56297868"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). There have been postmarketing reports of traffic accidents, near-miss incidents in traffic, or other accidental injuries in patients taking varenicline.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Postmarketing reports of hypersensitivity reactions (including angioedema) and rare cases of serious skin reactions (including Stevens-Johnson syndrome and erythema multiforme) have been reported. Patients should be instructed to discontinue use and contact health care provider if signs/symptoms occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required with severe impairment.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F56297989"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Varenicline has not demonstrated efficacy in patients ≤16 years; the manufacturer conducted a randomized, double-blind, placebo-controlled trial including 216 pediatric patients 12 to 16 years of age as part of the Pediatric Research Equity Act which showed that varenicline did not increase smoking abstinence rates compared to placebo in this age group (FDA 2019).</p></div>
<div class="block foc drugH1Div" id="F56297912"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">APO-Varenicline: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">APO-Varenicline: 1 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chantix: 0.5 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chantix: 1 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chantix Continuing Month Pak: 1 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chantix Starting Month Pak: 0.5 MG X 11 &amp; 1 MG X 42 (53 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 MG X 11 &amp; 1 MG X 42 (53 ea)</p></div>
<div class="block geq drugH1Div" id="F56297857"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F56297917"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Varenicline Tartrate (Starter) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 MG X 11 &amp; 1 MG X 42 (per each): $6.72 - $9.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Varenicline Tartrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $6.36 - $9.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $6.36 - $9.28</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56297991"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Champix: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Champix: 1 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Champix Starter Pack: 0.5 MG X 11 &amp; 1 MG X 14 (25 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 MG X 11 &amp; 1 MG X 14 (25 ea)</p></div>
<div class="block admp drugH1Div" id="F56297833"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer after eating and with a full glass of water.</p></div>
<div class="block adm drugH1Div" id="F56297901"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer after eating and with a full glass of water.</p></div>
<div class="block sts drugH1Div" id="F56297882"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block meg drugH1Div" id="F56297850"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F021928s048lbl.pdf%23page%3D22&amp;token=JEr2e23IXyYfKrs5I4t9OIn0gUw5NcOmIvLGKeziDMxnrU95B8%2BgpLbCg1CV2XfhMPtXeM8yR3%2FHhZK11cBt4vWt6NdAs2JBJ9uQDmTofw%2FyjvRh1G0dczE5OeyfVcAE&amp;TOPIC_ID=134149" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021928s048lbl.pdf#page=22</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F56297996"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment to aid in smoking cessation (FDA approved in ages ≥17 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F56297877"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT2</p></div>
<div class="block dri drugH1Div" id="F56297874"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): Varenicline (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, alcohol tolerance may be decreased and the risk for neuropsychiatric adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicotine: Varenicline (Systemic) may enhance the adverse/toxic effect of Nicotine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F56297900"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take after eating and with a full glass of water to decrease gastric upset.</p></div>
<div class="block pri drugH1Div" id="F56297864"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The incidence of adverse pregnancy outcomes following maternal use of varenicline is not greater in comparison to pregnancy outcomes of pregnant patients who smoke (Pedersen 2020; Tran 2020; Turner 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Varenicline is approved for use as an aid to smoking cessation. Adverse pregnancy outcomes are associated with maternal cigarette smoking (refer to Nicotine monograph for details). All pregnant patients should be screened for nicotine use, regardless of form (cigarettes, e-cigarettes, hookahs, snus, vaping products, as well as lozenges, patches, and gum). Cessation of intake is recommended, and interventions should be individualized (ACOG 2020). The benefit of tobacco smoking cessation for pregnant patients is well documented; behavioral interventions are effective and recommended. Information related to pharmacotherapy interventions in pregnancy is limited and insufficient to make specific recommendations (USPSTF [Krist 2021]). When behavioral counseling is insufficient, the severity of maternal tobacco dependance should be considered along with the known risks of smoking and possible risks of the pharmacologic intervention (ACOG 2020; USPSTF [Krist 2021]). The efficacy of varenicline as an aid to smoking cessation in pregnancy has not been established (Claire 2020; USPSTF [Krist 2021]).</p></div>
<div class="block mopp drugH1Div" id="F56297997"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for behavioral changes and psychiatric symptoms (eg, agitation, depression, suicidal behavior, suicidal ideation).</p></div>
<div class="block pha drugH1Div" id="F56297883"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Partial neuronal α<sub>4</sub> β<sub>2</sub> nicotinic receptor agonist; prevents nicotine stimulation of mesolimbic dopamine system associated with nicotine use disorder. Also binds to 5-HT<sub>3</sub> receptor (significance not determined) with moderate affinity. Varenicline stimulates dopamine activity but to a much smaller degree than nicotine does, resulting in decreased craving and withdrawal symptoms.</p></div>
<div class="block phk drugH1Div" id="F56297884"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed; unaffected by food</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ≤20%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimal (&lt;10% of clearance is through metabolism)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~90%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: ~3 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (92% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F56297885"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function:</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate renal impairment (CrCl ≥30 to ≤50 mL/minute): Drug exposure increased 1.5-fold</p>
<p style="text-indent:-2em;margin-left:4em;">Severe renal impairment (CrCl &lt;30 mL/minute): Drug exposure increased 2.1-fold</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD requiring hemodialysis: Drug exposure increased 2.7-fold</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56297920"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Champix</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Chantix</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Vtix</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Champix | Champix Starter Pack | Champix Titration Pack</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32332417">
<a name="32332417"></a>American College of Obstetricians and Gynecologists (ACOG). Tobacco and nicotine cessation during pregnancy: ACOG committee opinion, number 807. <i>Obstet Gynecol</i>. 2020;135(5):e221-e229. doi:10.1097/AOG.0000000000003822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/32332417/pubmed" id="32332417" target="_blank">32332417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27116918">
<a name="27116918"></a>Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. <i>Lancet</i>. 2016;387(10037):2507-2520. doi: 10.1016/S0140-6736(16)30272-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/27116918/pubmed" id="27116918" target="_blank">27116918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24042367">
<a name="24042367"></a>Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. <i>Ann Intern Med</i>. 2013;159(6):390-400. doi: 10.7326/0003-4819-159-6-201309170-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/24042367/pubmed" id="24042367" target="_blank">24042367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30527452">
<a name="30527452"></a>Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. <i>J Am Coll Cardiol</i>. 2018;72(25):3332-3365. doi:10.1016/j.jacc.2018.10.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/30527452/pubmed" id="30527452" target="_blank">30527452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29630702">
<a name="29630702"></a>Benowitz NL, Pipe A, West R, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. <i>JAMA Intern Med</i>. 2018;178(5):622-631. doi:10.1001/jamainternmed.2018.0397<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/29630702/pubmed" id="29630702" target="_blank">29630702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27158893">
<a name="27158893"></a>Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. <i>Cochrane Database Syst Rev</i>. 2016;2016(5):CD006103. doi:10.1002/14651858.CD006103.pub7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/27158893/pubmed" id="27158893" target="_blank">27158893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32077187">
<a name="32077187"></a>Carney G, Bassett K, Maclure M, Taylor S, Dormuth CR. Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study. <i>Addiction</i>. 2020;115(8):1534-1546 doi:10.1111/add.14951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/32077187/pubmed" id="32077187" target="_blank">32077187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chantix.1">
<a name="Chantix.1"></a>Chantix (varenicline) [prescribing information]. New York, NY: Pfizer Labs; February 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25083271">
<a name="25083271"></a>Chelladurai Y, Singh S. Varenicline and cardiovascular adverse events: a perspective review. <i>Ther Adv Drug Saf</i>. 2014;5(4):167-172. doi:10.1177/2042098614530421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/25083271/pubmed" id="25083271" target="_blank">25083271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31252274">
<a name="31252274"></a>Chopra DA, Shah AB, Vadhariya AH, Painter JT. The risk of varenicline-induced seizure among those who have attempted to quit smoking using pharmacotherapy. <i>Epilepsy Behav</i>. 2019;97:169-173. doi:10.1016/j.yebeh.2019.05.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/31252274/pubmed" id="31252274" target="_blank">31252274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32129504">
<a name="32129504"></a>Claire R, Chamberlain C, Davey MA, et al. Pharmacological interventions for promoting smoking cessation during pregnancy. <i>Cochrane Database Syst Rev</i>. 2020;3(3):CD010078. doi:10.1002/14651858.CD010078.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/32129504/pubmed" id="32129504" target="_blank">32129504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24906297">
<a name="24906297"></a>Erken HA, Erken G, Simşek H, et al. Single dose varenicline may trigger epileptic activity. <i>Neurol Sci</i>. 2014;35(11):1807-12. doi:10.1007/s10072-014-1845-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/24906297/pubmed" id="24906297" target="_blank">24906297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18617085">
<a name="18617085"></a>Fiore M, Jaen CR, Baker TB, et al, “A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update. A U.S. Public Health Service Report,” <i>Am J Prev Med</i>, 2008, 35(2):158-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/18617085/pubmed" id="18617085" target="_blank">18617085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). FDA in brief: FDA updates label for Chantix with data underscoring it's not effective in children 16 and younger. Published February 22, 2019. Accessed October 3, 2019. <a href="https://www.fda.gov/news-events/fda-brief/fda-brief-fda-updates-label-chantix-data-underscoring-its-not-effective-children-16-and-younger" target="_blank">https://www.fda.gov/news-events/fda-brief/fda-brief-fda-updates-label-chantix-data-underscoring-its-not-effective-children-16-and-younger</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24030388">
<a name="24030388"></a>Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. <i>Am J Psychiatry</i>. 2013;170(12):1460-1467. doi: 10.1176/appi.ajp.2013.12121599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/24030388/pubmed" id="24030388" target="_blank">24030388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31609433">
<a name="31609433"></a>Gray KM, Baker NL, McClure EA, et al. Efficacy and safety of varenicline for adolescent smoking cessation: a randomized clinical trial [published online October 14, 2019]. <i>JAMA Pediatr</i>. 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/31609433/pubmed" id="31609433" target="_blank">31609433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518946">
<a name="21518946"></a>Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. <i>Arch Intern Med.</i> 2011;171(8):770-777.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/21518946/pubmed" id="21518946" target="_blank">21518946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33464343">
<a name="33464343"></a>Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force (USPSTF). Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. <i>JAMA</i>. 2021;325(3):265-279. doi:10.1001/jama.2020.25019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/33464343/pubmed" id="33464343" target="_blank">33464343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32663106">
<a name="32663106"></a>Leone FT, Zhang Y, Evers-Casey S, et al. Initiating pharmacologic treatment in tobacco-dependent adults. An official American Thoracic Society (ATS) clinical practice guideline. <i>Am J Respir Crit Care Med</i>. 2020;202(2):e5-e31. doi:10.1164/rccm.202005-1982ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/32663106/pubmed" id="32663106" target="_blank">32663106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26037950">
<a name="26037950"></a>Molero Y, Lichtenstein P, Zetterqvist J, Gumpert CH, Fazel S. Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study. <i>BMJ</i>. 2015;350:h2388. doi:10.1136/bmj.h2388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/26037950/pubmed" id="26037950" target="_blank">26037950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31713302">
<a name="31713302"></a>Pedersen L, Petronis KR, Nørgaard M, et al. Risk of adverse birth outcomes after maternal varenicline use: a population-based observational study in Denmark and Sweden. <i>Pharmacoepidemiol Drug Saf</i>. 2020;29(1):94-102. doi:10.1002/pds.4894<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/31713302/pubmed" id="31713302" target="_blank">31713302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31502736">
<a name="31502736"></a>Peng AR, Swardfager W, Benowitz NL, et al. Impact of early nausea on varenicline adherence and smoking cessation. <i>Addiction</i>. 2020;115(1):134-144. doi:10.1111/add.14810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/31502736/pubmed" id="31502736" target="_blank">31502736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rigotti.1">
<a name="Rigotti.1"></a>Rigotti NA. Pharmacotherapy for smoking cessation in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 9, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25409105">
<a name="25409105"></a>Savage RL, Zekarias A, Caduff-Janosa P. Varenicline and abnormal sleep related events. <i>Sleep</i>. 2015;38(5):833-837. doi:10.5665/sleep.4686<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/25409105/pubmed" id="25409105" target="_blank">25409105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925501">
<a name="30925501"></a>Seak CJ, Goh ZNL, Seak JC, Seak CK, Li CH. Life-threatening angioedema following varenicline administration. <i>J Clin Psychopharmacol</i>. 2019;39(3):285-287. doi:10.1097/JCP.0000000000001036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/30925501/pubmed" id="30925501" target="_blank">30925501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21287775">
<a name="21287775"></a>Serafini A, Crespel A, Velizara R, Gelisse P. Varenicline-induced grand mal seizure. <i>Epileptic Disord</i>. 2010;12(4):338. doi:10.1684/epd.2010.0339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/21287775/pubmed" id="21287775" target="_blank">21287775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21727225">
<a name="21727225"></a>Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. <i>CMAJ</i>. 2011;183(12):1359-1366. doi:10.1503/cmaj.110218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/21727225/pubmed" id="21727225" target="_blank">21727225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26903004">
<a name="26903004"></a>Sterling LH, Windle SB, Filion KB, Touma L, Eisenberg MJ. Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. <i>J Am Heart Assoc</i>. 2016;5(2):e002849. doi:10.1161/JAHA.115.002849<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/26903004/pubmed" id="26903004" target="_blank">26903004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21606948">
<a name="21606948"></a>Swan GE, Javitz HS, Jack LM, et al. Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes. <i>Pharmacogenomics J</i>. 2012;12(4):349-358. doi:10.1038/tpj.2011.19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/21606948/pubmed" id="21606948" target="_blank">21606948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25767129">
<a name="25767129"></a>Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. <i>BMJ</i>. 2015;350:h1109. doi:10.1136/bmj.h1109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/25767129/pubmed" id="25767129" target="_blank">25767129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26514264">
<a name="26514264"></a>Tobin TJ, Tobin ML. Clinical psychopharmacology update: Additional safety concerns for using varenicline (<i>Chantix</i>) for smoking cessation treatment. <i>Issues Ment Health Nurs</i>. 2015;36(10):840-843. doi:10.3109/01612840.2015.1053769<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/26514264/pubmed" id="26514264" target="_blank">26514264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16820548">
<a name="16820548"></a>Tonstad S, Tønneson P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. <i>JAMA.</i> 2006;296(1):64-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/16820548/pubmed" id="16820548" target="_blank">16820548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32019533">
<a name="32019533"></a>Tran DT, Preen DB, Einarsdottir K, et al. Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study. <i>BMC Med</i>. 2020;18(1):15. doi:10.1186/s12916-019-1472-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/32019533/pubmed" id="32019533" target="_blank">32019533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29579233">
<a name="29579233"></a>Turner E, Jones M, Vaz LR, Coleman T. Systematic review and meta-analysis to assess the safety of bupropion and varenicline in pregnancy. <i>Nicotine Tob Res</i>. 2019;21(8):1001-1010. doi:10.1093/ntr/nty055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/29579233/pubmed" id="29579233" target="_blank">29579233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23615317">
<a name="23615317"></a>Ware JH, Vetrovec GW, Miller AB, et al. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials. <i>Am J Ther</i>. 2013;20(3):235-246. doi:10.1097/MJT.0b013e31828d455b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varenicline-systemic-pediatric-drug-information/abstract-text/23615317/pubmed" id="23615317" target="_blank">23615317</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 134149 Version 111.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
